Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Profit After Tax: 2009-2025

Historic Profit After Tax for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -$306.2 million.

  • Cytokinetics' Profit After Tax fell 90.71% to -$306.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$752.0 million, marking a year-over-year decrease of 30.46%. This contributed to the annual value of -$589.5 million for FY2024, which is 12.03% down from last year.
  • As of Q3 2025, Cytokinetics' Profit After Tax stood at -$306.2 million, which was down 127.86% from -$134.4 million recorded in Q2 2025.
  • Cytokinetics' 5-year Profit After Tax high stood at -$19.8 million for Q2 2022, and its period low was -$306.2 million during Q3 2025.
  • Over the past 3 years, Cytokinetics' median Profit After Tax value was -$136.9 million (recorded in 2023), while the average stood at -$156.2 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 2,296.41% in 2021, then skyrocketed by 67.80% in 2022.
  • Cytokinetics' Profit After Tax (Quarterly) stood at -$30.6 million in 2021, then plummeted by 349.39% to -$137.4 million in 2022, then rose by 0.35% to -$136.9 million in 2023, then decreased by 9.59% to -$150.0 million in 2024, then tumbled by 90.71% to -$306.2 million in 2025.
  • Its last three reported values are -$306.2 million in Q3 2025, -$134.4 million for Q2 2025, and -$161.4 million during Q1 2025.